BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best up and coming stocks with huge upside potential. On August 28, BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics to $87 from $78, while keeping a Buy rating on the shares, citing estimate changes following Q2 2025 results.

The Q2 2025 financial results showed that Apogee Therapeutics had a strong cash position of $621.2 million in cash, cash equivalents, and marketable securities at the end of the quarter. The financial runway is expected to support operations into Q1 2028.

Apogee announced positive 16-week topline data from Part A of its Phase 2 APEX trial for APG777, which is a potential best-in-class treatment for moderate-to-severe atopic dermatitis/AD. The trial met all primary and key secondary endpoints, with APG777 demonstrating a 71% reduction in Eczema Area and Severity Index/EASI from baseline, compared to 33.8% for placebo.

Apogee Therapeutics Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company that develops novel biologics for the treatment of atopic dermatitis/AD, asthma, eosinophilic esophagitis/EoE, chronic obstructive pulmonary disease/COPD, and other inflammatory and immunology indications.

While we acknowledge the potential of APGE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.